Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 19, 2026Clinical Cancer Research

Abstract PS5-04-02: Interim results: Real world study of treatment discontinuations and modifications for patients with HER2-positive metastatic breast cancer on trastuzumab deruxtecan on a Canadian patient support program

View Full Paper
Ask AI
Bookmark
Share

Authors

CBChristine Brezden‐MasleyCardio-OncologySSSimran ShokarAstraZeneca (Canada)ANA. NamAstraZeneca (Canada)

Discussion

Loading...

Member takes

Implication

Observational study reveals treatment discontinuation rates in HER2-positive metastatic breast cancer patients, suggesting early challenges in therapy management.

Key Points

  • The study aims to describe real-world treatment outcomes for HER2-positive metastatic breast cancer patients receiving trastuzumab deruxtecan in Canada.
  • Observational study design involving patients enrolled in a Canadian patient support program.
  • Data collected from June 2022 to August 2023, focusing on treatment initiation and modifications.
  • Primary outcomes included rates of treatment discontinuation and dose modifications using descriptive summaries.
  • 347 patients were enrolled, with a median follow-up of 5.6 months.
  • Cumulative probabilities of treatment discontinuation at 3, 6, and 9 months were 10.2%, 18.2%, and 29.7%, respectively.
  • Median time to treatment discontinuation was reported as 14.3 months overall, and 15.2 months for patients with stable brain metastases.

Cite This Study

Brezden‐Masley et al. (2026) studied this question.

synapsesocial.com/papers/6996a85cecb39a600b3eef43https://doi.org/10.1158/1557-3265.sabcs25-ps5-04-02
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract PS2-06-08: Interim results: Real world study of treatment discontinuations and modifications for patients with HER2-low metastatic breast cancer on trastuzumab deruxtecan on a Canadian patient support program2026
  2. 2Abstract PS1-10-30: Real-world treatment utilization and outcomes of trastuzumab deruxtecan (T-DXd) among patients with hormone receptor-positive (HR+) HER2-low metastatic breast cancer (mBC) in the United States2026
  3. 3Abstract PS5-05-20: Real-world treatment patterns and outcomes in patients with HER2+ metastatic breast cancer after treatment with trastuzumab deruxtecan (T-DXd) in the US2026
  4. 4Canadian real-world hybrid longitudinal cohort study of treatment discontinuations and modifications for patients with HER2+ and HER2-low metastatic breast cancer on trastuzumab deruxtecan enrolled in a patient support programme: the HER-TEMPO study protocol2025
  5. 5Abstract PS5-04-07: Real world experience with trastuzumab deruxtecan for metastatic breast cancer at a major Australian cancer centre2026